For decades, the medical community has faced a frustrating void in the treatment of cocaine use disorder (CUD). While clinicians have a robust toolkit for treating opioid or alcohol dependence, there has been a glaring absence of FDA-approved medications specifically designed to help people stop using cocaine. Patients have largely been left to rely on behavioral therapies—which, while valuable, often struggle to overcome the intense physiological cravings associated with the drug.
A new clinical trial from the University of Alabama at Birmingham (UAB) suggests that a breakthrough may be on the horizon. Published in JAMA Network Open, the study indicates that psilocybin—the naturally occurring psychedelic compound found in “magic mushrooms”—is not only safe but effective in helping individuals achieve and maintain cocaine abstinence.
As a physician, I have seen how the “treatment gap” for stimulant use disorders leaves some of the most vulnerable patients without a lifeline. The UAB study is particularly significant because it doesn’t just test a new compound; it intentionally addresses the lack of diversity in psychedelic research, recruiting participants from underrepresented communities who have historically been excluded from these high-profile trials.
A New Approach to Breaking the Cycle
The study, led by Peter Hendricks, Ph.D., a professor in the Department of Psychiatry and Behavioral Neurobiology at UAB, was built on the premise that psilocybin could “reset” the brain’s reward circuitry. This hypothesis follows previous research showing the compound’s effectiveness in treating nicotine and alcohol addictions.
The treatment was not a simple pill-and-pill approach. Instead, the researchers employed a comprehensive therapeutic model. Participants were randomized to receive either a single oral dose of psilocybin (25 milligrams per 70 kilograms of body weight) or an active placebo. To ensure the psychological experience was integrated into lasting change, the drug session was bookended by cognitive behavioral therapy (CBT)—one month of preparation before the session and one month of follow-up care afterward.
The results, tracked over 180 days through follow-up interviews and urinalysis, showed a clear advantage for the psilocybin group. Those who received the psychedelic compound experienced a higher percentage of cocaine-abstinent days and a significantly lower risk of relapse over time compared to the placebo group.
Study Outcomes at a Glance
| Metric | Psilocybin Group Outcome | Placebo Group Outcome |
|---|---|---|
| Abstinence Days | Higher percentage of drug-free days | Lower percentage of drug-free days |
| Complete Abstinence | Greater likelihood of total cessation | Lower likelihood of total cessation |
| Relapse Risk | Reduced risk of cocaine lapse | Higher risk of cocaine lapse |
| Primary Side Effect | Transient hypertension (resolved) | Minimal reported effects |
Prioritizing Equity in Psychedelic Medicine
One of the most striking aspects of this trial is its demographic composition. Much of the current “psychedelic renaissance” has been criticized for focusing on a narrow slice of the population—typically affluent, white participants. The UAB team intentionally pivoted away from this trend.
Of the 40 participants in the trial, 33 were Black and 33 were men. The majority of the participants reported an annual income of less than $20,000. By focusing on these populations, the researchers are providing critical data on how psilocybin works across different socioeconomic and racial backgrounds, ensuring that if these treatments become mainstream, they are effective for everyone, not just a privileged few.
Understanding the Limitations
While the results are promising, the medical community views this as a “proof of concept” rather than a final answer. We find several caveats that must be considered before this can be translated into standard clinical practice.
First, the sample size was small, consisting of only 40 individuals, with 36 completing the full 180-day assessment. In the world of clinical trials, larger, multi-site studies are required to prove efficacy beyond a reasonable doubt. Second, the lead investigator also served as the primary therapist, which introduces a potential for bias that is difficult to quantify.
Perhaps most importantly, because the psilocybin was administered alongside intensive CBT, it is difficult to isolate exactly how much of the success was due to the drug itself and how much was due to the psychological support. However, the disparity between the psilocybin group and the placebo group—who also received CBT—suggests that the compound provides a synergistic boost that therapy alone cannot achieve.
Regarding safety, the researchers noted that the most common adverse effect was hypertension (high blood pressure). Fortunately, this was transient and resolved on its own without medical intervention, supporting the general conclusion that the treatment is safe when administered in a controlled, clinical setting.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Psilocybin remains a controlled substance in many jurisdictions. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
The next phase for this research involves moving toward larger, more standardized trials to refine the therapeutic process and ensure replicability. Researchers will be looking to determine if the same dosing schedule works across even broader populations and whether the duration of the CBT support can be optimized for better long-term outcomes.
We want to hear from you. Do you believe psychedelic-assisted therapy is the future of addiction treatment? Share your thoughts in the comments below or share this story with your network.
